Diagnostic value of computed high b-value whole‐body diffusion-weighted imaging for primary prostate cancer

Purpose To investigate the utility of post-acquisition computed diffusion-weighted imaging (cDWI) for primary prostate cancer (PCa) evaluation in biparametric whole‐body MRI (bpWB-MRI). Methods Patients who underwent pelvic PCa screening and subsequent bpWB-MRI staging were included. Two radiologists assessed diagnostic performance following datasets clinically significant diagnosis (grade group ≥2 according to Prostate Imaging-Reporting Data System, version 2.1): bpMRI2000 (axial DWI scans with a b-value 2,000 s/mm2 + axial T2WI from pre-biopsy MRI), bpWB-MRI2000 (computed WB-DWI WB-T2WI scans), native bpWB-MRI1000 (native 1,000 scans). Systemic biopsy was used as reference standard. Results Fifty-one patients The areas under curve (AUCs) (0.89 reader 1 0.86 2) (0.86 0.83 significantly higher (p < 0.001) than those (0.67 both readers). No difference observed between AUCs = 0.10 p 0.25 2). Conclusions similar that dedicated evaluation. cDWI can be recommended implementation standard WB-MRI protocols facilitate one-step concurrent detection metastatic PCa.